IDT and Sanofi to manufacture mRNA vaccines under development

Drug development company IDT Australia and pharmaceutical business Sanofi have signed an agreement for the good manufacturing practice (cGMP) manufacture of Sanofi’s mRNA vaccines now under development. The partners will collaborate to advance mRNA-based vaccine formulation, development and manufacture at IDT’s aseptic sterile injectables filling facilities in Melbourne (pictured) in volumes needed for clinical trials…

Manufacturing news briefs — stories you might have missed

Viraleze shows efficacy in Covid-19 patients – Starpharma Starpharma’s Viraleze antiviral nasal spray has demonstrated antiviral efficacy in a placebo-controlled study in participants with Covid-19. Viraleze achieved a statistically significant reduction in SARS-CoV-2 viral load, in the cohort of participants aged 45 and over. Viral load in the nose was reduced by 80 percent less…

Vaxxas needle free vaccines have great potential – study

Needle free vaccine delivery company Vaxxas‘s skin patch system is an attractive alternative to vaccine delivery via injection, according to a new study. Published in the journal Vaccine, the study said the company’s high-density microarray patch (HD-MAP) (pictured) was particularly attractive in a pandemic. Its’ use would alleviate the strain on healthcare systems by enabling…

Apprenctice starts remain above pandemic levels – NCVER

Apprentice and trainee commencements appear to be returning to levels seen before the onset of the Covid-19 pandemic, according to the latest data from the National Centre for Vocational Education Research (NCVER). The Apprentices and trainees 2023: March quarter report shows that apprentice and trainee commencements increased steeply during the pandemic. While they have declined…